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Abstract
OBJECTIVES—The severity of liver disease in the hepatitis C virus (HCV)-infected population 
in the United States remains uncertain. We estimated the prevalence of cirrhosis in adults with 
chronic hepatitis C (CHC) using multiple parameters including liver biopsy, diagnosis/procedure 
codes, and a biomarker.
METHODS—Patients enrolled in the Chronic Hepatitis Cohort Study (CHeCS) who received 
health services during 2006–2010 were included. Cirrhosis was identified through liver biopsy 
reports, diagnosis/procedure codes for cirrhosis or hepatic decompensation, and Fibrosis-4 (FIB-4) 
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scores ≥5.88. Demographic and clinical characteristics associated with cirrhosis were identified 
through multivariable logistic modeling.
RESULTS—Among 9,783 patients, 2,788 (28.5%) were cirrhotic by at least one method. Biopsy 
identified cirrhosis in only 661 (7%) patients, whereas FIB-4 scores and diagnosis/procedure 
codes for cirrhosis and hepatic decompensation identified cirrhosis in 2,194 (22%), 557 (6%), and 
482 (5%) patients, respectively. Among 661 patients with biopsy-confirmed cirrhosis, only 356 
(54%) had an International Classification of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM) code for cirrhosis. Older age, male gender, Asian race, Hispanic ethnicity, genotype 3 
infection, HIV coinfection, diabetes, history of antiviral therapy, and history of alcohol abuse were 
independently associated with higher odds of cirrhosis (all, P <0.05). Conversely, private health 
insurance coverage, black race, and HCV genotype 2 were associated with lower odds of cirrhosis.
CONCLUSIONS—A high proportion of patients with biopsy-confirmed cirrhosis are not 
assigned ICD-9 codes for cirrhosis. Consequently, ICD-9 codes may not be reliable as the sole 
indicator of the prevalence of cirrhosis in cohort studies. Use of additional parameters suggests a 
fourfold higher prevalence of cirrhosis than is revealed by biopsy alone. These findings suggest 
that cirrhosis in CHC patients may be significantly underdocumented and underdiagnosed.
INTRODUCTION
The health care and economic burden of chronic hepatitis C virus (HCV) infection in the 
United States relates primarily to liver disease severity. Recent estimates suggest that 1% of 
the noninstitutionalized civilian population in the United States is chronically HCV infected, 
corresponding to ~ 2.7 million individuals (1). Progression of chronic hepatitis C (CHC) to 
cirrhosis occurs over a period of several years (2). The identification of patients with 
cirrhosis may have significant implications pertaining to the management of CHC and health 
resource utilization (3).
A recent multicohort natural history model of CHC projected an increase in the proportion 
of CHC patients with cirrhosis from 25% in 2010 to 45% in 2030 (4). A subsequent 
retrospective cohort study of a national sample of veterans in the United States reported an 
increase in the prevalence of HCV-related cirrhosis from 9% in 1996 to 18.5% in 2006 and 
an increase in the prevalence of decompensated cirrhosis from 5% to 11% over the same 
period (5). Both studies postulated that the aging of the HCV-infected population and 
duration of HCV infection accounts for the increase in the prevalence of cirrhosis; others 
have shown that this progression to cirrhosis is significantly associated with Hispanic 
ethnicity, socioeconomic status, and metabolic factors (e.g., hepatic steatosis, obesity, insulin 
resistance, and diabetes) (6–14).
Although these published estimates of cirrhosis prevalence highlight the significant burden 
of cirrhosis associated with chronic HCV infection, they may nevertheless underestimate the 
true prevalence of cirrhosis. This notion is supported by our recent observation that 
estimated that at least two-thirds of all HCV-infected individuals who died in 2010 were 
likely to have had unrecognized premortem indications of chronic liver disease (15). 
Previous estimates of the prevalence of cirrhosis have included patients whose cirrhosis was 
confirmed by liver biopsy or defined based on the presence of International Classification of 
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Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for cirrhosis or hepatic 
decompensation in patient records (5,16,17). These estimates may have failed to capture a 
substantial proportion of patients with cirrhosis because liver biopsy is not routinely 
performed in clinical practice. Moreover, preferential diagnostic coding for the underlying 
HCV infection over the code for cirrhosis may result in erroneous estimates.
The Fibrosis-4 (FIB-4), a simple noninvasive index based on readily available demographic 
and laboratory parameters, has been previously validated as being able to accurately predict 
advanced fibrosis in HCV-infected patients with and without HIV coinfection (18–20). We 
have previously shown the FIB-4 index to be superior to other serum marker indices of liver 
fibrosis (e.g., the aspartate aminotransferase-to-platelet ratio index (APRI) and the aspartate 
aminotransferase-to-alanine aminotransferase ratio) in its ability to differentiate between 
mild-to-moderate and advanced fibrosis for CHC patients in the Chronic Hepatitis Cohort 
Study (CHeCS) cohort, a large, geographically and racially diverse cohort receiving routine 
care at four large US health-care systems (21,22). A subsequent study in the same cohort 
validated the FIB-4 index for both CHC and chronic hepatitis B and determined optimal 
cutoff values for differentiating between F0–F2 (no to moderate fibrosis), F3 (advanced 
fibrosis), and F4 (cirrhosis) (23). In the present study, we sought to estimate the prevalence 
of cirrhosis among CHC patients in the CHeCS cohort based on an expanded set of 
parameters that included FIB-4 as well as liver biopsy results and the presence of diagnosis 
or procedure codes for cirrhosis and various manifestations of hepatic decompensation.
METHODS
Study population
The CHeCS cohort—a dynamic, prospective, longitudinal, observational, multicenter cohort
—and the process used for cohort selection have been previously described (22). Adults ≥18 
years of age who met CHeCS electronic identification criteria, whose CHC infection was 
confirmed through chart abstraction, and who received any type of health service between 1 
January 2006 and 31 December 2010 at any of the four health systems participating in the 
CHeCS (Geisinger Health System, Danville, PA; Henry Ford Health System, Detroit, MI 
(coordinating center); Kaiser Permanente Northwest, Portland, OR; and Kaiser Permanente, 
Honolulu, HI) were included in this study. Patients were excluded if they were coinfected 
with the hepatitis B virus, if they had achieved a sustained viral response to therapy, or if 
they were liver transplant recipients.
The CHeCS study protocol was approved at each participating site between October 2009 
and February 2010 by an institutional review board approved by the Federal Office for 
Human Research Protections.
Data collection and analysis
Data pertaining to routine care through the end of 2010 were collected from the electronic 
health record and supplemented with individual chart review; these included patient 
demographics, medical encounters, laboratory results, diagnoses, and procedures including 
liver biopsy results (22). Data regarding the source of infection were collected through a 
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patient survey, with patients being permitted to select more than one likely source of 
infection. Self-reported data from the same survey were used to determine the date of 
infection. Data on household income were estimated from US census data based on 
geocoded addresses. Data on antiviral treatment were collected by chart abstraction and 
included any available documentation of treatment received at outside facilities. Data on 
HCV genotypes were collected from laboratory records. History of alcohol abuse was 
determined on the basis of presence of an ICD-9-CM diagnosis code related to past or 
present alcohol abuse (291.0–291.9, 303.00–303.93, 305.00–305.03, or 980.0) in the 
patients’ medical records. Coinfection with HIV was determined by the presence of HIV 
antibodies or a detected HIV RNA level on quantitative or qualitative testing. Diabetes 
comorbidity was defined on the basis of the Charlson/Deyo comorbidity subscore for 
diabetes, defined as the presence of an ICD-9-CM diagnosis score for diabetes (250.xx) in 
the medical record (24).
Cirrhosis was identified from four sources: (i) liver biopsy reports (Metavir stage 4 or, if 
cirrhosis had not been staged, the narrative diagnosis by a pathologist); (ii) presence of at 
least one ICD-9-CM diagnosis code for cirrhosis (571.2 and 571.5); (iii) presence of at least 
one ICD-9-CM diagnosis or procedure code or Current Procedural Terminology (CPT) code 
associated with a manifestation of hepatic decompensation (Table 1); and (iv) FIB-4 index 
score. In addition, APRI was used in a sensitivity analysis. The FIB-4 and APRI indices 
were calculated as previously described (18,23,25). For FIB-4, a cutoff value of ≥5.88 that 
has been previously validated as being predictive of cirrhosis in this cohort (23) was used, 
whereas cutoff values of >1.0, >1.5, and >2.0 were used for the APRI index. The most 
recent values for aminotransferase levels and platelet counts that had been collected within 7 
days of each other were used. Aminotransferase levels and platelet counts taken during 
antiviral therapy were excluded as therapy can influence these parameters. A second 
sensitivity analysis that excluded laboratory values collected while patients were 
hospitalized was performed in order to eliminate the potential influence of spurious platelet 
and/or aminotransferase derangements during hospitalization.
Statistical methods
Logistic regression—univariate, followed by multivariable modeling— was used to compare 
the demographic and clinical characteristics of patients with and without an indication of 
cirrhosis (by any of the four methods). Variables with P value of <0.05 were retained in the 
final multivariable model.
RESULTS
Population characteristics
Table 2 shows the demographic characteristics of the study population (n =9,783). The mean 
age of the patients was 55±10.9 years at the time of most recent follow-up. More than one-
half of them were white males and a majority (94%) were insured. Of all patients, 43% had 
at least one liver biopsy report during follow-up, 17% of whom had a recent biopsy <2 years 
old. The median follow-up time was 6.4 years.
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Indication of cirrhosis
Of the 9,783 patients in the cohort, cirrhosis was indicated by at least one method in 2,788 
patients (28.5%) (Table 3). Of these, 2,194 (22.4%) had FIB-4 scores ≥5.88, 661 patients 
(6.8%) were diagnosed with cirrhosis by liver biopsy, and 751 patients (7.7%) had 
diagnostic/procedure codes for cirrhosis or manifestations of hepatic decompensation (of 
whom 557 patients (5.7%) and 482 patients (4.9%) had diagnostic or procedure codes for 
cirrhosis and hepatic decompensation, respectively). Cirrhosis was indicated exclusively by 
FIB-4 scores in 1,727 patients (17.6%) and was indicated by all methods (FIB-4 score, liver 
biopsy, and presence of a diagnostic/procedure code for cirrhosis or hepatic 
decompensation) in only 221 patients (2.3%). Notably, of the 661 patients with cirrhosis 
identified by biopsy, only 356 (53.9%) also had ICD-9-CM/CPT codes for cirrhosis or 
manifestations of hepatic decompensation (Supplementary Table S1 online).
Among the 2,194 patients whose FIB-4 scores were ≥5.88, only 357 patients (16%) had 
been diagnosed with cirrhosis by liver biopsy results, whereas 326 patients (15%) had 
ICD-9-CM/CPT codes for cirrhosis or manifestations of hepatic decompensation. When 
APRI scores >1.0, >1.5, and >2.0 were also taken into consideration, cirrhosis was indicated 
in 1,659 (75.6%), 1,402 (63.8%), and 1,186 (54.0%) patients, respectively; cirrhosis 
remained indicated solely by FIB-4 scores in only 433 patients (19.7%) (Supplementary 
Table S2). Of the 2,194 patients with cirrhosis indicated by FIB-4 scores ≥5.88, only 788 
patients (36%) had a biopsy performed at any time (Supplementary Table S3). Of these 788 
patients, 357 patients (45%) had a biopsy indicating cirrhosis (concordance), whereas 
cirrhosis was not indicated in the remaining 431 patients (55%). Discordance between 
cirrhosis indicated by FIB-4 scores and by biopsy was seen in only 431 of the 2,194 patients 
(19.6%).
We explored the possibility that this discordance may have been due to the performance of 
the biopsy significantly earlier than the FIB-4 score calculation. The discordance could 
indicate that the FIB-4 score represents a true progression to cirrhosis during the time 
interval between the two tests. We therefore analyzed differences in the timing of the FIB-4 
relative to the timing of the biopsy in the 788 patients who had cirrhosis as indicated by 
FIB-4 scores and had a biopsy performed, comparing patients showing concordance with 
those showing discordance with regard to the two measures. We compared the elapsed time 
of the earliest indication of cirrhosis by FIB-4 scores from the time of biopsy. The median 
elapsed time from biopsy to FIB-4 was 37.9 months among the patients with concordance 
and 46.8 months in patients with discordance (including negative times in cases where the 
biopsy was performed after FIB-4 scores were calculated). Although the differences between 
the two groups was not significant based on a nonparametric Wilcoxon test, it is possible 
that a cirrhotic FIB-4 score measured almost 4 years after a noncirrhotic biopsy could indeed 
represent progression to cirrhosis.
Sensitivity analysis
In the second sensitivity analysis, exclusion of FIB-4 scores from lab values collected during 
hospitalizations resulted in a reduction in the number of patients with FIB-4 scores ≥5.88 
from 2,185 (22%) to 1,757 (18%). There was a corresponding decrease in the overall 
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number of patients with an indication of cirrhosis by at least one of the methods from 2,788 
(28%) to 2,422 (25%).
Demographic and clinical characteristics of patients with cirrhosis
Univariate analysis of the demographic and clinical characteristics of patients with an 
indication of cirrhosis (by any of the four methods), compared with those without indication 
of cirrhosis, revealed that age, gender, race/ethnicity, median annual household income, 
insurance status, receipt of any HCV antiviral therapy, HCV genotype, history of alcohol 
abuse, HIV coinfection, and diabetes (as assessed by the Charlson/Deyo comorbidity 
subscore) were significantly associated with prevalence of cirrhosis in this cohort (Table 4). 
Multivariable logistic modeling for characteristics associated with cirrhosis revealed that 
older age, male gender, Asian race (compared with White race), Hispanic ethnicity, lack of 
insurance coverage or coverage by Medicare or Medicaid (compared with private insurance), 
history of receipt of antiviral therapy, infection by HCV genotype 3 (compared with 
infection by genotype 1), history of alcohol abuse, HIV coinfection, and diabetes were 
associated with being cirrhotic (Table 5). Conversely, Black race and infection with HCV 
genotype 2 were associated with lower odds of being cirrhotic.
Source of infection
We collected data regarding source of infection among a subgroup of 4,218 patients who 
completed a survey to examine whether mode of infection was associated with development 
of cirrhosis (indicated by FIB-4 ≥5.88, biopsy, or diagnosis codes). In univariate analysis, 
we found that contracting hepatitis C through occupational exposure, blood transfusion, or a 
medical procedure was associated with higher rates of cirrhosis, whereas exposure by 
injection drug use or sex with males was associated with lower rates of cirrhosis 
(Supplementary Table S4).
Duration of infection
Data on the duration of infection were available for a subgroup of patients who completed a 
survey and were able to estimate when they became infected (n =2,389). Of these, 365 
patients were indicated as having cirrhosis by FIB-4 ≥5.88, whereas 2,024 patients were 
determined not to have cirrhosis by FIB-4. To improve our confidence in FIB-4 as a 
predictor of cirrhosis, we used logistic regression analysis to examine whether, as we 
hypothesized, a longer duration of infection was associated with FIB-4-cirrhosis. We found 
that the odds of cirrhosis as indicated by FIB-4 increased with duration of infection (odds 
ratio=1.09 for each 5-year duration of infection; 95% Wald confidence interval 1.04–1.14, P 
<0.0001).
DISCUSSION
This study revealed that the use of parameters in addition to liver biopsy—including a 
previously validated serum biomarker that serves as a surrogate for more advanced fibrosis
—facilitates the identification of previously unrecognized cirrhotic CHC patients. Use of all 
four parameters (liver biopsy, FIB-4 scores, and diagnostic/procedural codes for cirrhosis 
and manifestations of hepatic decompensation) suggests a fourfold higher prevalence of 
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cirrhosis than is indicated by biopsy alone. The estimated prevalence of cirrhosis of 25–28% 
in the CHC population at four health systems in the United States is in agreement with the 
previously modeled projection of 25% prevalence of cirrhosis in 2010 (4). These results 
imply that a quarter of all CHC patients under medical care may be cirrhotic, but that most 
have never been formally assigned this diagnosis and may be unaware of their cirrhosis. 
Moreover, only half of all patients with biopsy-confirmed cirrhosis are assigned an ICD-9 
code for cirrhosis. Consequently, ICD-9 codes may not be reliable as the sole indicator of 
the prevalence of cirrhosis in cohort studies.
The present analysis corroborates earlier reports indicating that age, alcohol abuse, male 
gender, coinfection with HIV, and diabetes are associated with a significant increase in the 
risk of progression to cirrhosis (14,26–29). Our observation that Hispanic ethnicity increases 
the risk of progression to cirrhosis is in agreement with findings of other studies that have 
evaluated the role of ethnicity in the progression of hepatitis C infections to cirrhosis (6–9); 
similarly, our finding that African Americans are at lower risk of cirrhosis compared with 
Caucasians is also in agreement with findings of other studies (8,27,29,30). Our finding that 
HCV infection acquired through blood transfusion is associated with higher rates of 
cirrhosis is in agreement with earlier retrospective studies that reported more aggressive 
histological inflammatory activity and a higher risk of hepatic decompensation in patients 
with transfusion-acquired hepatitis C (31,32). Our observation that duration of infection is a 
significant risk factor for the development of cirrhosis as assessed by FIB-4 corroborates 
earlier reports that showed duration of infection to be an independent predictor of advanced 
fibrosis in hepatitis C-infected individuals (33,34). Our observation that the duration of 
infection is positively associated with a higher likelihood of FIB-4-indicated cirrhosis also 
suggests that the FIB-4 test is a reliable predictor of cirrhosis. Finally, our observations that 
infection with HCV genotype 3 increases the risk of cirrhosis compared with infection with 
genotype 1, and that infection with HCV genotype 2 is associated with a lower risk for 
cirrhosis, are consistent with the recently-reported findings of Kanwal et al. (35). That HCV 
viral genotype influences response to antiviral therapy has been long recognized, but the 
finding that genotype actually affects liver disease progression is a recent finding that has 
significant implications regarding the modeling of this viral epidemic.
Our study has significant strengths, including the large size and diversity of the cohort 
(22,36). The cohort is drawn from four large integrated health systems that serve almost 4 
million individuals in five geographically and racially distinct states. This study is unique 
because it used an expanded set of parameters (liver biopsy, the serum fibrosis marker 
FIB-4, and the presence of diagnostic/procedure codes for cirrhosis and manifestations of 
hepatic decompensation) to identify CHC patients with cirrhosis. The FIB-4 index employed 
in our study has been extensively validated in this large cohort for its ability to predict the 
lower and upper ends of the liver fibrosis spectrum (F0–F2 and cirrhosis, respectively) in 
both patients with hepatitis B virus infection and HCV infection (23). The FIB-4 cutoff 
value of 5.88 that we used to identify cirrhosis in this study is conservative. In the original 
validation study of FIB-4 in this cohort, a value of 1.81 differentiated fibrosis stages 3–4 
from fibrosis stages 0–2. Accordingly, use of this lower cutoff would have identified an even 
higher proportion of CHC patients with advanced fibrosis, some with cirrhosis but with 
FIB-4 between 1.81 and 5.88. It must be emphasized, however, that this study reports period 
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prevalence of cirrhosis between 2006 and 2010, and not the prevalence at a single point in 
time.
Our study has inherent limitations. The FIB-4 index is based on laboratory values (alanine 
and aspartate aminotransferase values and platelet counts) that may fluctuate over time, and 
such natural fluctuations may occur during the course of HCV infection. However, we used 
the most recently available aminotransferase levels and platelet counts collected within 7 
days of each other, rather than peak values, reducing the likelihood that we captured 
spurious elevations. Furthermore, we excluded laboratory values collected while a patient 
was receiving antiviral therapy in order to eliminate any influence of therapy on these 
laboratory values. Our sensitivity analysis also excluded laboratory values collected from 
hospitalized patients who may have had spurious platelet count or aminotransferase values 
during hospitalization for reasons unrelated to their liver disease. Although the FIB-4 score 
has been shown to have an area under the receiver operating characteristic curve value of 
85% in predicting cirrhosis in our cohort (23), it is not diagnostic and does not identify 
cirrhosis in patients with low or normal transaminase levels and those who have normal 
platelet counts. Although we would have liked to combine this noninvasive test score with an 
assessment of liver stiffness to improve the test performance, the observational nature of our 
study precluded the collection of liver stiffness data. Moreover, liver stiffness tests had not 
been approved at the time of conduct of our study. Finally, the CHeCS cohort represents 
patients known to health systems and diagnosed with CHC; thus, our estimate of cirrhosis 
prevalence cannot be extrapolated to the undiagnosed HCV-infected population or to 
infected patients who have not had encounters with the health-care system.
Retrospective studies evaluating the economic impact of CHC, and Markov models 
evaluating the cost effectiveness of newer anti-HCV therapies, have typically relied on 
ICD-9 codes to identify and stratify patients on the basis of disease severity (17,37–40). Our 
finding that only one-half of all patients with biopsy-confirmed cirrhosis have ICD-9 codes 
assigned to them suggests that estimates of the economic burden reported by these 
retrospective studies and Markov models may be very conservative. Moreover, these cost-
effectiveness models are based on baseline estimates of the prevalence of cirrhosis. If the 
actual prevalence is higher than the current estimates, as is suggested by the results of our 
study, these models will need to be revised accordingly, which may result in significantly 
different findings with regard to the cost-effectiveness of the newer antiviral therapy 
regimens.
In conclusion, our study suggests that the prevalence of cirrhosis in CHC patients is higher 
than would be diagnosed through the use of liver biopsies and ICD-9 codes alone. 
Prospective studies of the natural history of CHC have reported the development of cirrhosis 
in 7–16% of patients over 8–16 years of follow-up (41–44), whereas retrospective–
prospective studies with exposure intervals of 9–45 years have reported progression to 
cirrhosis in 0.3–15% of CHC patients (45–51). Our study also reveals that less than one-half 
of all CHC patients (43% in our cohort) underwent liver biopsy, and that use of additional 
parameters including FIB-4 scores and ICD-9/CPT codes for cirrhosis and hepatic 
decompensation likely facilitated a more accurate estimate of the prevalence of cirrhosis in a 
CHC population. Accurate estimation of the prevalence of advanced fibrosis or cirrhosis has 
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significant implications for patient care and health-care policy. There has been recent interest 
in the use of noninvasive modalities including elastography and blood tests for the diagnosis 
of liver fibrosis in patients with hepatitis C, and the use of these noninvasive modalities in 
lieu of liver biopsy has been widely discussed (52,53). Our findings suggest that the use of 
FIB-4 and APRI scores facilitates more accurate estimation of the prevalence of cirrhosis in 
CHC patients than would be possible through the use of biopsy alone. Serum markers such 
as FIB-4 and APRI scores, which are easily calculable with online tools that use readily 
available demographic and laboratory parameters (54), could prove clinically useful if 
included as part of the comprehensive clinical profile of CHC patients. Cirrhosis has likely 
been underdiagnosed in the past because of patient reluctance to undergo liver biopsy. Use 
of these noninvasive modalities will help address this underdiagnosis and provide more 
reliable estimates of the true prevalence of advanced fibrosis. Knowledge of the actual 
prevalence of advanced fibrosis will also help inform clinical decision making regarding 
screening for sequelae of CHC, timing of initiation of antiviral therapy, and follow-up 
counseling. Our findings are the first in the United States to attempt an accurate estimate of 
the prevalence of cirrhosis in the CHC patient population at large. These findings heighten 
awareness of the health-care burden imposed by advancing HCV disease progression in the 
US population.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
• The prevalence of chronic hepatitis C (CHC)-related cirrhosis is uncertain.
• Previous studies may underestimate the true prevalence of cirrhosis in CHC 
patients.
WHAT IS NEW HERE
• Use of additional parameters to identify cirrhosis suggests a fourfold higher 
prevalence compared with liver biopsy alone.
• A significant proportion of patients with biopsy-confirmed cirrhosis are not 
assigned International Classification of Diseases, Ninth Revision (ICD-9) 
codes for cirrhosis.
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Table 1
Diagnosis/procedure codes for manifestations of hepatic decompensation
Condition ICD-9-CM and CPT diagnosis and procedure codes
Liver cancer 155.0, 155.1, 155.2
Liver failure with hepatorenal syndrome 572.4
Hepatic encephalopathy 572.2
Portal hypertension/portal decompression procedures 572.3
37140, 37160, 37180, 37181, 37182, 37183
Esophageal varices complications and procedures 456.0, 456.20
43204, 43205, 43243, 43244, 43400, 43401
42.91, 44.91, 96.06
Other GI hemorrhage (selected) 530.7, 530.82, 578.0, 578.1, 578.9
Ascites/paracentesis procedures 789.5, 789.59
49080, 49081
54.91
Other sequelae of chronic liver disease 572.8
CPT, Current Procedural Terminology; GI, gastrointestinal; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical 
Modification.
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Table 2
Population characteristics
Characteristic N =9,783
Agea (mean, s.d.) 55.0 (10.9)
Age categorya
 ≤40 years 807 (8%)
 >40 to <50 years 1,464 (15%)
 >50 to <60 years 4,513 (46%)
 ≥60 years 2,999 (31%)
Male sex 5,752 (59%)
Race
 Asian 311 (3%)
 White 5,963 (61%)
 Black 2,267 (23%)
 Pacific Islander/Hawaiian 190 (2%)
 Native American 177 (2%)
 Unknown 875 (9%)
Hispanic ethnicity 366 (4%)
Median annual household incomeb
 <$15,000 253 (3%)
 ≥$15,000 to <$30,000 1,877 (19%)
 ≥$30,000 to <$50,000 4,424 (45%)
 ≥$50,000 to <$75,000 2,147 (22%)
 ≥$75,000 548 (6%)
 Missing 534 (6%)
Insurance statusb
 Medicaid 1,256 (13%)
 Medicare 2,281 (23%)
 Private 5,623 (57%)
 None 289 (3%)
 Unknown 334 (3%)
Any HCV antiviral therapy 3,586 (37%)
HCV genotype
 1 4,687 (48%)
 2 830 (8%)
 3 613 (6%)
 Other 117 (1%)
 Unknown 3,536 (36%)
History of alcohol abuse 2,262 (23%)
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Characteristic N =9,783
HIV coinfection 319 (3%)
Diabetes (Charlson/Deyo comorbidity subscore) 967 (10%)
HCV, hepatitis C virus.
aAt the time of most recent follow-up through 31 December 2010.
bAt the time of enrollment into Chronic Hepatitis Cohort Study (CHeCS).
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Table 3
Proportion of patients with cirrhosis indicated vs. not indicated
N (%); n =9,783
Cirrhosis not indicated 6,995 (71.5)
Cirrhosis indicated by FIB-4 scores, liver biopsy, or diagnostic/procedure codes for cirrhosis or manifestations of hepatic 
decompensation
2,788 (28.5)
 By FIB-4 ≥5.88 2,194 (22.4)
 By liver biopsy 661 (6.8)
 By diagnostic/procedure codes (for cirrhosis or manifestations of hepatic decompensation) 751 (7.7)
  By ICD-9-CM diagnostic codes for cirrhosis 557 (5.7)
  By ICD-9 diagnostic codes/CPT codes for manifestations of hepatic decompensation 482 (4.9)
 By APRI >1.0a 1,825 (18.7)
 By APRI >1.5a 1,488 (15.2)
 By APRI >2.0a 1,231 (12.6)
APRI, aspartate aminotransferase-to-platelet ratio index; CPT, Current Procedural Terminology; FIB-4, Fibrosis-4; ICD-9-CM, International 
Classification of Diseases, Ninth Revision, Clinical Modification.
aAPRI scores served as additional criteria for determination of cirrhosis in sensitivity analyses.
Am J Gastroenterol. Author manuscript; available in PMC 2017 December 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gordon et al. Page 18
Table 4
Univariate logistic comparisons of demographic and clinical characteristics among patients with an indication 
of cirrhosis (by any method) and those without an indication of cirrhosis
Characteristic No indication of cirrhosis, n =6,995 Indication of cirrhosis, n =2,788 P value a
Age (mean, s.d.) 53.6 (11.3) 58.5 (8.9) <0.001
Age category <0.001
 ≤40 years 771 (11%) 36 (1%)
 >40 to <50 years 1,193 (17%) 271 (10%)
 >50 to <60 years 3,103 (44%) 1,410 (51%)
≥60 years 1,928 (28%) 1,071 (38%)
Male sex 3,950 (56%) 1,802 (65%) <0.001
Race <0.001
 Asian 193 (3%) 118 (4%)
 White 4,416 (63%) 1,547 (55%)
 Black 1,485 (21%) 782 (28%)
 Pacific Islander/Hawaiian 121 (2%) 69 (2%)
 Native American 129 (2%) 48 (2%)
 Unknown 651 (9%) 224 (8%)
Hispanic ethnicity 237 (3%) 129 (5%) <0.001
Median annual household income <0.001
 <$15,000 172 (2%) 81 (3%)
 ≥$15,000 to <$30,000 1,302 (19%) 575 (21%)
 ≥$30,000 to <$50,000 3,146 (45%) 1,278 (46%)
 ≥$50,000 to <$75,000 1,556 (22%) 591 (21%)
 ≥$75,000 399 (6%) 149 (5%)
 Missing 420 (6%) 114 (4%)
Insurance status <0.001
 Medicaid 887 (13%) 369 (13%)
 Medicare 1,379 (20%) 902 (32%)
 Private 4,307 (62%) 1,316 (47%)
 None 183 (3%) 106 (4%)
 Unknown 239 (3%) 95 (3%)
Any HCV antiviral therapy 2,429 (35%) 1,157 (41%) <0.001
HCV genotype <0.001
 1 3,229 (46%) 1,458 (52%)
 2 636 (9%) 194 (7%)
 3 415 (6%) 198 (7%)
 Other 85 (1%) 32 (1%)
 Unknown 2,630 (38%) 906 (32%)
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Characteristic No indication of cirrhosis, n =6,995 Indication of cirrhosis, n =2,788 P value a
History of alcohol abuse 1,349 (19%) 913 (33%) <0.001
HIV coinfection 182 (3%) 137 (5%) <0.001
Diabetes (Charlson/Deyo comorbidity subscore) 603 (9%) 364 (13%) <0.001
HCV, hepatitis C virus.
aP values for categorical variables are based on the chi-square test, while the P value for the continuous variable (age) is based on the t-test 
(unequal variance).
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Table 5
Multivariable logistic model of characteristics associated with cirrhosis (indicated by any method)
Characteristic Adjusted odds ratio (95% CI) P value
Age category <0.001
 <40 years 1 (reference)
 >40–50 years 5.04 (3.49–7.28)*
 >50–60 years 10.65 (7.49–15.15)*
 ≥60 years 12.63 (8.81–18.11)*
Sex 0.003
 Male 1 (reference)
 Female 0.86 (0.78–0.95)*
Race <0.001
 White 1 (reference)
 Asian 1.59 (1.22–2.06)*
 Black 0.81 (0.70–0.92)*
 Pacific Islander/Hawaiian 1.28 (0.90–1.80)
 Native American 0.97 (0.68–1.39)
Hispanic ethnicity <0.001
 Not Hispanic 1 (reference)
 Hispanic 1.36 (1.05–1.75)*
Insurance <0.001
 Private 1 (reference)
 Medicaid 1.80 (1.54–2.11)*
 Medicare 1.73 (1.54–1.94)*
 No insurance 2.14 (1.62–2.82)*
Any HCV antiviral therapy <0.001
 No 1 (reference)
 Yes 1.43 (1.29–1.58)*
HCV genotype <0.001
 1 1 (reference)
 2 0.74 (0.62–0.89)*
 3 1.27 (1.04–1.55)*
 Other 0.99 (0.63–1.54)
History of alcohol abuse <0.001
 No 1 (reference)
 Yes 2.32 (2.08–2.59)*
HIV coinfection <0.001
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Characteristic Adjusted odds ratio (95% CI) P value
 No 1 (reference)
 Yes 1.86 (1.45–2.39)*
Diabetes (Charlson/Deyo comorbidity subscore) <0.001
 No 1 (reference)
 Yes 1.39 (1.18–1.64)*
95% CI, 95% confidence interval; HCV, hepatitis C virus.
*Adjusted odds ratio is statistically significant at alpha = 0.05 level.
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